{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:04:49Z","timestamp":1765814689870,"version":"3.48.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>\n                    Direct-acting antiviral (DAA) therapy is now the recommended standard for chronic hepatitis C (CHC), demonstrating remarkable efficacy. Nonetheless, there is a relative lack of information concerning the sustained, long-term consequences of DAA treatment. Therefore, this study sought to investigate the long-term impact of DAA therapy on patients with CHC. We conducted a retrospective review of CHC patients who received DAA therapy at Samsung Changwon Hospital. Patients with preexisting hepatocellular carcinoma (HCC) and those lost to follow-up were excluded. Demographic, clinical, and virological data were analyzed, focusing on DAA treatment outcomes, liver fibrosis, and the relationship with HCC development. A total of 223 patients were included: 59.5% with CHC genotype 1, 93.3% treatment-na\u00efve, and 26.5% with liver cirrhosis (LC). Treatment included asunaprevir and daclatasvir in 46.2%, with 46.2% receiving a 12-week regimen. Sustained virological response at 12 weeks (SVR12) was achieved in 97.8%, with 5 treatment failures. Post-treatment, APRI scores\u2005&lt;\u20050.7 increased (68.2% vs 87.7%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), as did FIB-4 scores\u2005&lt;\u20053.25 (60.1% vs 80.3%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). During follow-up, 9 patients developed HCC, with serum sodium identified as a risk factor (odds ratio: 0.6; confidence interval: 0.41\u20130.88;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008). DAA treatment effectively treats CHC and reduces liver fibrosis. However, further research is warranted to better understand and predict the development of HCC.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046449","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:01:24Z","timestamp":1765814484000},"page":"e46449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7128-2518","authenticated-orcid":false,"given":"Bo Ram","family":"Sung","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-7039","authenticated-orcid":false,"given":"Sang Goon","family":"Shim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3048-2376","authenticated-orcid":false,"given":"Kwang Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-1618","authenticated-orcid":false,"given":"Jung Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-9212","authenticated-orcid":false,"given":"Jun Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8445-6381","authenticated-orcid":false,"given":"Bo Kyeong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2257","authenticated-orcid":false,"given":"Cheon Hoo","family":"Jun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Soo","family":"Kwan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C.","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update.","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.coviro.2016.09.010","article-title":"Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.","volume":"20","author":"Bandiera","year":"2016","journal-title":"Curr Opin Virol"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1089-3261(05)70237-3","article-title":"Overview of interferon therapy for chronic hepatitis C.","volume":"3","author":"Ahmed","year":"1999","journal-title":"Clin Liver Dis"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1345\/aph.19183","article-title":"Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection.","volume":"34","author":"Battaglia","year":"2000","journal-title":"Ann Pharmacother"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jvh.12529","article-title":"New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.","volume":"23","author":"Harris","year":"2016","journal-title":"J Viral Hepat"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","article-title":"New approaches in the treatment of hepatitis C.","volume":"22","author":"Gonz\u00e1lez-Grande","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.7314\/APJCP.2012.13.12.5917","article-title":"Hepatitis C virus--proteins, diagnosis, treatment and new approaches for vaccine development.","volume":"13","author":"Keyvani","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3350\/cmh.2018.1002","article-title":"Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD\/IDSA and 2016 EASL.","volume":"24","author":"Yeon","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3748\/wjg.v26.i22.2931","article-title":"Liver-related effects of chronic hepatitis C antiviral treatment.","volume":"26","author":"Laursen","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2018.11.016","article-title":"Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals.","volume":"51","author":"Trivedi","year":"2019","journal-title":"Dig Liver Dis"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000500963","article-title":"Treatment of chronic hepatitis C: efficacy, side effects and complications.","volume":"35","author":"Sandmann","year":"2019","journal-title":"Visc Med"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.gastrohep.2022.03.007","article-title":"Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C.","volume":"46","author":"Neokosmidis","year":"2023","journal-title":"Gastroenterol Hepatol"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2169\/internalmedicine.55.5780","article-title":"Hyponatremia associated with hepatocellular carcinoma.","volume":"55","author":"Kwon Ma","year":"2016","journal-title":"Intern Med"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.3748\/wjg.v20.i25.8158","article-title":"Hepatocellular carcinoma treated by c onventional transarterial chemoembolization in field-practice: serum sodium predicts survival.","volume":"20","author":"Biolato","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.3748\/wjg.v20.i18.5442","article-title":"Cirrhosis and its complications: evidence based treatment.","volume":"20","author":"Nusrat","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jceh.2021.10.145","article-title":"Impact of hyponatremia on morbidity, mortality, and resource utilization in portal hypertensive ascites: a nationwide analysis.","volume":"12","author":"Thuluvath","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3904\/kjim.2019.297","article-title":"Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma.","volume":"36","author":"Kwan","year":"2021","journal-title":"Korean J Intern Med"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14740338.2019.1617272","article-title":"Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis.","volume":"18","author":"Galati","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3748\/wjg.v28.i1.96","article-title":"Risk of hepatocellular carcinoma after hepatitis C virus cure.","volume":"28","author":"Luna-Cuadros","year":"2022","journal-title":"World J Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:01:28Z","timestamp":1765814488000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":23,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046449","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-07-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}